Loading stock data…
LEGN
$23.59+0.07 (+0.30%)
Market ClosedLast close May 1
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Legend Biotech Corporation in the Healthcare sector is trading at $23.59. The stock is currently 48% below its 52-week high of $45.30, remaining 12.8% below its 200-day moving average. Technical signals show overbought RSI of 74 and bullish MACD crossover, explaining why LEGN maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 74) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$23.59
Potential Upside
5%
Whystock Fair Value$24.77
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Buy
Mean target$57.23+142.6%
Range$21.00 – $86.00
Fundamentals
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.80B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.08
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.62%
Volume
Today's trading volume
995,865
Recent News
H.C. Wainwright Reaffirms Buy Rating for Legend Biotech (LEGN)
Legend Biotech Corp. (NASDAQ:LEGN) is one of the 10 best biotech stocks with highest upside potential. On April 20, H.C. Wainwright maintained its Buy rating for Legend Biotech Corp. (NASDAQ:LEGN). The firm has projected a target price of $50, which yields more than 109% potential upside for investors. It highlighted the company’s CAR-T therapies and […]
Legend Biotech CARVYKTI Milestones Contrast With Mixed Long Term Share Returns
Legend Biotech reported that more than 10,000 patients have now been treated with its CARVYKTI multiple myeloma therapy. The company announced an expansion of its Raritan facility, which it says is now the largest cell therapy manufacturing site in the US. These updates highlight a step up in both commercial usage and production capacity for CARVYKTI. For investors watching NasdaqGS:LEGN, these milestones arrive after a period of mixed share price performance. The stock last closed at...
Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?
Legend Biotech (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Legend Biotech (LEGN) Gets Bullish Ratings, PT Hike, Soars 18%
Legend Biotech Corp. (NASDAQ:LEGN) is one of the 10 Stocks With Double-Digit Returns. Legend Biotech soared for a 5th straight day on Monday, climbing 18.42 percent to close at $25.07 apiece, as investors took heart from two investment firms’ reiteration of bullish coverage for its stock. In a market note, RBC Capital reaffirmed its “outperform” […]
Why Legend Biotech Stock Crushed the Market on Monday
Two analysts weighed in positively about the company's future.